-
N649351-1mgNVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4In VitroNVP-BHG712 isomer exhibits IC 50 values of 163 nM and 1660 nM for EPHA2 and EPHA4, respectively. MCE has not independently confirmed the
-
N649351-50mgNVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4In VitroNVP-BHG712 isomer exhibits IC 50 values of 163 nM and 1660 nM for EPHA2 and EPHA4, respectively. MCE has not independently confirmed the
-
N649351-5mgNVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4In VitroNVP-BHG712 isomer exhibits IC 50 values of 163 nM and 1660 nM for EPHA2 and EPHA4, respectively. MCE has not independently confirmed the
-
N655819-1mlNVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4In VitroNVP-BHG712 isomer exhibits IC 50 values of 163 nM and 1660 nM for EPHA2 and EPHA4, respectively. MCE has not independently confirmed the
-
U649903-10mgUniPR129 is a potent Eph/ephrin antagonist. UniPR129 has the potential for the research of cancer disease.Form:Solid
-
U649903-25mgUniPR129 is a potent Eph/ephrin antagonist. UniPR129 has the potential for the research of cancer disease.Form:Solid
-
U649903-50mgUniPR129 is a potent Eph/ephrin antagonist. UniPR129 has the potential for the research of cancer disease.Form:Solid
-
U649903-5mgUniPR129 is a potent Eph/ephrin antagonist. UniPR129 has the potential for the research of cancer disease.Form:Solid
-
U648457-10mgUrolithin D is competitive and reversible antagonist of EphA receptors. Urolithin D exhibits intra-classes selectivity.Form:Solid
-
U648457-25mgUrolithin D is competitive and reversible antagonist of EphA receptors. Urolithin D exhibits intra-classes selectivity.Form:Solid
-
U648457-5mgUrolithin D is competitive and reversible antagonist of EphA receptors. Urolithin D exhibits intra-classes selectivity.Form:Solid